← Eichor
Study identifier: NCT06310330 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Condition: Breast Neoplasm Malignant Primary  ·  Sponsor: Norwegian University of Science and Technology

PhaseNA
Planned participants250
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD). Secondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.

This description comes directly from the study's public registry record.

Talk to the study team

Espen Holte, MD. PhD  ·  92243119  ·  espen.holte@stolav.no

Havard Dalen, MD, PhD  ·  95871716  ·  havard.dalen@ntnu.no

Always discuss trial participation with your own doctor first.

Locations (1)

St. Olavs hospitalTrondheim, NorwayRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06310330